374 related articles for article (PubMed ID: 26256523)
1. Transcriptional changes induced by candidate malaria vaccines and correlation with protection against malaria in a human challenge model.
Dunachie S; Berthoud T; Hill AV; Fletcher HA
Vaccine; 2015 Sep; 33(40):5321-31. PubMed ID: 26256523
[TBL] [Abstract][Full Text] [Related]
2. A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge.
Dunachie SJ; Walther M; Epstein JE; Keating S; Berthoud T; Andrews L; Andersen RF; Bejon P; Goonetilleke N; Poulton I; Webster DP; Butcher G; Watkins K; Sinden RE; Levine GL; Richie TL; Schneider J; Kaslow D; Gilbert SC; Carucci DJ; Hill AV
Infect Immun; 2006 Oct; 74(10):5933-42. PubMed ID: 16988273
[TBL] [Abstract][Full Text] [Related]
3. A three-antigen Plasmodium falciparum DNA prime-Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults.
Sklar MJ; Maiolatesi S; Patterson N; Sedegah M; Limbach K; Teneza-Mora N; Chuang I; Hollis-Perry KM; Banania JG; Guzman I; Ganeshan H; Reyes S; Hollingdale MR; Wong M; Lindstrom A; Reyes A; Alcorta Y; Garver L; Bankard K; Belmonte A; Belmonte M; Huang J; Gowda K; Inoue S; Velasco R; Bergmann-Leitner E; Hutter J; Lee T; Adams N; Chaudhury S; Hunt D; Tamminga C; Berrie E; Bellamy D; Bittaye M; Ewer K; Diggs C; Soisson LA; Lawrie A; Hill A; Richie TL; Villasante E; Epstein JE; Duplessis CA
PLoS One; 2021; 16(9):e0256980. PubMed ID: 34495988
[TBL] [Abstract][Full Text] [Related]
4. Sequential Phase 1 and Phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS,S and TRAP formulated with AS02 Adjuvant System in healthy, malaria naïve adults.
Kester KE; Gray Heppner D; Moris P; Ofori-Anyinam O; Krzych U; Tornieporth N; McKinney D; Delchambre M; Ockenhouse CF; Voss G; Holland C; Beckey JP; Ballou WR; Cohen J;
Vaccine; 2014 Nov; 32(49):6683-91. PubMed ID: 24950358
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the Plasmodium falciparum Preerythrocytic Antigen UIS3 as a Potential Candidate for a Malaria Vaccine.
Longley RJ; Halbroth BR; Salman AM; Ewer KJ; Hodgson SH; Janse CJ; Khan SM; Hill AVS; Spencer AJ
Infect Immun; 2017 Mar; 85(3):. PubMed ID: 28031267
[TBL] [Abstract][Full Text] [Related]
6. DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity.
Chuang I; Sedegah M; Cicatelli S; Spring M; Polhemus M; Tamminga C; Patterson N; Guerrero M; Bennett JW; McGrath S; Ganeshan H; Belmonte M; Farooq F; Abot E; Banania JG; Huang J; Newcomer R; Rein L; Litilit D; Richie NO; Wood C; Murphy J; Sauerwein R; Hermsen CC; McCoy AJ; Kamau E; Cummings J; Komisar J; Sutamihardja A; Shi M; Epstein JE; Maiolatesi S; Tosh D; Limbach K; Angov E; Bergmann-Leitner E; Bruder JT; Doolan DL; King CR; Carucci D; Dutta S; Soisson L; Diggs C; Hollingdale MR; Ockenhouse CF; Richie TL
PLoS One; 2013; 8(2):e55571. PubMed ID: 23457473
[TBL] [Abstract][Full Text] [Related]
7. Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal.
Mensah VA; Gueye A; Ndiaye M; Edwards NJ; Wright D; Anagnostou NA; Syll M; Ndaw A; Abiola A; Bliss C; Gomis JF; Petersen I; Ogwang C; Dieye T; Viebig NK; Lawrie AM; Roberts R; Nicosia A; Faye B; Gaye O; Leroy O; Imoukhuede EB; Ewer KJ; Bejon P; Hill AV; Cisse B;
PLoS One; 2016; 11(12):e0167951. PubMed ID: 27978537
[TBL] [Abstract][Full Text] [Related]
8. MIG and the regulatory cytokines IL-10 and TGF-β1 correlate with malaria vaccine immunogenicity and efficacy.
Dunachie SJ; Berthoud T; Keating SM; Hill AV; Fletcher HA
PLoS One; 2010 Sep; 5(9):e12557. PubMed ID: 20838432
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals.
Hodgson SH; Ewer KJ; Bliss CM; Edwards NJ; Rampling T; Anagnostou NA; de Barra E; Havelock T; Bowyer G; Poulton ID; de Cassan S; Longley R; Illingworth JJ; Douglas AD; Mange PB; Collins KA; Roberts R; Gerry S; Berrie E; Moyle S; Colloca S; Cortese R; Sinden RE; Gilbert SC; Bejon P; Lawrie AM; Nicosia A; Faust SN; Hill AV
J Infect Dis; 2015 Apr; 211(7):1076-86. PubMed ID: 25336730
[TBL] [Abstract][Full Text] [Related]
10. Novel sporozoite-based ELISpot assay to assess frequency of parasite-specific B cells after vaccination with irradiated sporozoites.
Atre T; Robinson TM; Savransky T; Dutta S; Epstein JE; Bergmann-Leitner ES
Malar J; 2019 May; 18(1):186. PubMed ID: 31142328
[TBL] [Abstract][Full Text] [Related]
11. Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection.
Tamminga C; Sedegah M; Maiolatesi S; Fedders C; Reyes S; Reyes A; Vasquez C; Alcorta Y; Chuang I; Spring M; Kavanaugh M; Ganeshan H; Huang J; Belmonte M; Abot E; Belmonte A; Banania J; Farooq F; Murphy J; Komisar J; Richie NO; Bennett J; Limbach K; Patterson NB; Bruder JT; Shi M; Miller E; Dutta S; Diggs C; Soisson LA; Hollingdale MR; Epstein JE; Richie TL
Hum Vaccin Immunother; 2013 Oct; 9(10):2165-77. PubMed ID: 23899517
[TBL] [Abstract][Full Text] [Related]
12. A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults.
Moorthy VS; Imoukhuede EB; Milligan P; Bojang K; Keating S; Kaye P; Pinder M; Gilbert SC; Walraven G; Greenwood BM; Hill AS
PLoS Med; 2004 Nov; 1(2):e33. PubMed ID: 15526058
[TBL] [Abstract][Full Text] [Related]
13. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.
Polhemus ME; Magill AJ; Cummings JF; Kester KE; Ockenhouse CF; Lanar DE; Dutta S; Barbosa A; Soisson L; Diggs CL; Robinson SA; Haynes JD; Stewart VA; Ware LA; Brando C; Krzych U; Bowden RA; Cohen JD; Dubois MC; Ofori-Anyinam O; De-Kock E; Ballou WR; Heppner DG
Vaccine; 2007 May; 25(21):4203-12. PubMed ID: 17442466
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.
Ogwang C; Afolabi M; Kimani D; Jagne YJ; Sheehy SH; Bliss CM; Duncan CJ; Collins KA; Garcia Knight MA; Kimani E; Anagnostou NA; Berrie E; Moyle S; Gilbert SC; Spencer AJ; Soipei P; Mueller J; Okebe J; Colloca S; Cortese R; Viebig NK; Roberts R; Gantlett K; Lawrie AM; Nicosia A; Imoukhuede EB; Bejon P; Urban BC; Flanagan KL; Ewer KJ; Chilengi R; Hill AV; Bojang K
PLoS One; 2013; 8(3):e57726. PubMed ID: 23526949
[TBL] [Abstract][Full Text] [Related]
15. Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine.
Lalvani A; Moris P; Voss G; Pathan AA; Kester KE; Brookes R; Lee E; Koutsoukos M; Plebanski M; Delchambre M; Flanagan KL; Carton C; Slaoui M; Van Hoecke C; Ballou WR; Hill AV; Cohen J
J Infect Dis; 1999 Nov; 180(5):1656-64. PubMed ID: 10515829
[TBL] [Abstract][Full Text] [Related]
16. Liver-Directed AAV8 Booster Vaccine Expressing
Shahnaij M; Iyori M; Mizukami H; Kajino M; Yamagoshi I; Syafira I; Yusuf Y; Fujiwara K; Yamamoto DS; Kato H; Ohno N; Yoshida S
Front Immunol; 2021; 12():612910. PubMed ID: 34248928
[TBL] [Abstract][Full Text] [Related]
17. Irradiated sporozoite vaccination induces sex-specific immune responses and protection against malaria in mice.
Vom Steeg LG; Flores-Garcia Y; Zavala F; Klein SL
Vaccine; 2019 Jul; 37(32):4468-4476. PubMed ID: 31262583
[TBL] [Abstract][Full Text] [Related]
18. Early whole blood transcriptional responses to radiation-attenuated Plasmodium falciparum sporozoite vaccination in malaria naïve and malaria pre-exposed adult volunteers.
Duffy FJ; Du Y; Carnes J; Epstein JE; Hoffman SL; Abdulla S; Jongo S; Mpina M; Daubenberger C; Aitchison JD; Stuart K
Malar J; 2021 Jul; 20(1):308. PubMed ID: 34243763
[TBL] [Abstract][Full Text] [Related]
19. Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP.
Bliss CM; Bowyer G; Anagnostou NA; Havelock T; Snudden CM; Davies H; de Cassan SC; Grobbelaar A; Lawrie AM; Venkatraman N; Poulton ID; Roberts R; Mange PB; Choudhary P; Faust SN; Colloca S; Gilbert SC; Nicosia A; Hill AVS; Ewer KJ
Sci Rep; 2018 Feb; 8(1):3390. PubMed ID: 29467399
[TBL] [Abstract][Full Text] [Related]
20. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection.
Kester KE; Cummings JF; Ofori-Anyinam O; Ockenhouse CF; Krzych U; Moris P; Schwenk R; Nielsen RA; Debebe Z; Pinelis E; Juompan L; Williams J; Dowler M; Stewart VA; Wirtz RA; Dubois MC; Lievens M; Cohen J; Ballou WR; Heppner DG;
J Infect Dis; 2009 Aug; 200(3):337-46. PubMed ID: 19569965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]